Outcome of domino hematopoietic stem cell transplantation in human subjects: An international case series  Mirjam E. Belderbos, MD, PhD, Andrew R. Gennery, MBChB, MD, Christopher C. Dvorak, MD, Henric-Jan Blok, MSc, Dirk-Jan Eikema, PhD, Juliana M.F. Silva, MD, Paul Veys, MD, PhD, Bénédicte Neven, MD, PhD, Rebecca Buckley, MD, Theresa Cole, MD, Morton J. Cowan, MD, W. Scott Goebel, MD, PhD, Manfred Hoenig, MD, PhD, Caroline Y. Kuo, MD, E. Richard Stiehm, MD, Robert Wynn, MD, Marc Bierings, MD, PhD  Journal of Allergy and Clinical Immunology  Volume 142, Issue 5, Pages 1628-1631.e4 (November 2018) DOI: 10.1016/j.jaci.2018.06.030 Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Outcome of domino HSCT in human recipients. A, Schematic representation of domino HSCT. B-D, Outcome of recipients of primary HSCT recipients (recipient B in Fig 1, A), domino HSCT recipients (recipient C in Fig 1, A), and matched control subjects. E and F, Transplantation kinetics of primary and domino HSCT recipients. Each dot represents 1 recipient. G, Incidence of acute GvHD in primary and domino HSCT recipients. Tx, Transplantation. Journal of Allergy and Clinical Immunology 2018 142, 1628-1631.e4DOI: (10.1016/j.jaci.2018.06.030) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E1 Potential determinants of graft failure after domino HSCT. Depicted are total nucleated cell (TNC) dose (A), CD34+ cell dose (B), and time between primary and domino HSCT (C) in domino HSCT recipients who engrafted successfully and those who underwent later retransplantation. Each dot represents an individual domino HSCT recipient. Journal of Allergy and Clinical Immunology 2018 142, 1628-1631.e4DOI: (10.1016/j.jaci.2018.06.030) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions